Atara Biotherapeutics, Inc.
ATRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.01 | 0.00 | 0.04 |
| FCF Yield | -69.19% | -357.57% | -82.09% | -15.65% |
| EV / EBITDA | -1.56 | -0.32 | -1.47 | -4.22 |
| Quality | ||||
| ROIC | -3,538.01% | -778.47% | -90.16% | -93.27% |
| Gross Margin | 83.71% | -3.65% | 77.08% | 44.05% |
| Cash Conversion Ratio | 0.80 | 0.70 | 1.18 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | 26.58% | -25.02% | – | – |
| Free Cash Flow Growth | 64.49% | 29.28% | -18.83% | -24.74% |
| Safety | ||||
| Net Debt / EBITDA | -0.25 | -0.12 | 0.10 | 0.24 |
| Interest Coverage | -18.08 | -52.22 | -752.05 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.97 | 0.92 | 9.19 | 0.00 |
| Cash Conversion Cycle | 113.44 | 1,699.52 | 98.51 | -539.36 |